Sep 3, 2009

New Dimebon Clinical Trial Now Recruiting Participants

A new Dimebon Phase 3 clinical trial is now open and recruiting new participants. The study is called--A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease.
By Bob DeMarco
Alzheimer's Reading Room

Inclusion Criteria:
  • Men and women ≥ 50 years of age with a diagnosis of Alzheimers disease.
  • Have a Mini-Mental State Exam between 5 and 14 inclusive.
  • Have been taking the medication memantine (ie., Namenda) for at least six months prior to this study.
  • Must have a caregiver who assists the patient at least five days per week for at least three hours per day, who can accompany patient to study visits, and who has an intimate knowledge of the patient's health states and personal care.
Exclusion Criteria:
  • Have taken medicines for Alzheimers disease other than memantine (e.g., donepezil, rivastigmine, galantamine, tacrine) within 2 months prior to this study.
  • Dementia other than Alzheimers disease.
  • Any medical condition or reason that interferes with the ability of the patient to participate in or complete the trial or places the patient at undue risk, as judged by the study doctor.
The number of locations that are currently recruiting is limited, but additional locations are being added. If you are interested, but don't see a location near you, bookmark the clinical trials page and continue to check back from time to time. To get all the information about this recently opened Dimebon clinical trial go here

Subscribe to The Alzheimer's Reading Room--via Email

More About the Alzheimer's Reading Room

Bob DeMarco is the editor of the Alzheimer's Reading Room and an Alzheimer's caregiver. Bob has written more than 1,200 articles with more than 9,000 links on the Internet. Bob resides in Delray Beach, FL.

Original content Bob DeMarco, the Alzheimer's Reading Room